Opinion

Video

mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

Key Takeaways

  • The Inflation Reduction Act's cost cap will reduce financial burdens, enhancing access to oral chemotherapy for metastatic colorectal cancer patients.
  • Improved adherence to prescribed therapies is anticipated due to reduced out-of-pocket expenses, potentially leading to better treatment outcomes.
SHOW MORE

Medical experts discuss how the Inflation Reduction Act’s out-of-pocket prescription drug cost cap, effective in 2025, may impact access to oral chemotherapy options for metastatic colorectal cancer.

Video content above is prompted by the following:

Concerning access to these oral chemotherapy options, how do you anticipate the Inflation Reduction Act’s out-of-pocket prescription drug cost cap will impact access to these metastatic colorectal cancer therapies starting in 2025?

Related Videos
Marc Humbert, MD, PhD
John Ostrominski, MD
John Buse, MD, PhD
Christian T. Ruff, MD, MPH
Dr Geoffrey Rutledge
Jason Bellet of Eko Health
Dr Geoffrey Rutledge
3 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo